DNTH 8-K 2026-11-04

Dianthus Therapeutics, Inc. /DE/ (DNTH) 8-K dated 2026-11-04 — accession 0001690585-26-000039.

Dianthus Therapeutics, Inc. /DE/ (DNTH) is a biotechnology company listed on US.

Dianthus Therapeutics, Inc. /DE/ filed a 8-K on 2026-11-04. Accession 0001690585-26-000039.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported DNTH revenue for 2025-12-31 was $2.0M. Net income was -$162.3M. Revenue was down 67.3% from 2024-12-31 to 2025-12-31. DNTH currently screens at market cap $4.40B.

Not investment advice. The DNTH SEC hub lists recent forms. The stock page is the research view.